REverSe TRanscrIptase Chain Termination (RESTRICT) for Selective Measurement of Nucleotide Analogs Used in HIV Care and Prevention

Overview

Journal Bioeng Transl Med

Date 2023 Jan 23

PMID 36684094

Authors

Ayokunle O Olanrewaju

Benjamin P Sullivan

Alicia H Gim

Cosette A Craig

Derin Sevenler

Andrew T Bender

Paul K Drain

Jonathan D Posner

Affiliations

Soon will be listed here.

Abstract

Sufficient drug concentrations are required for efficacy of antiretroviral drugs used in HIV care and prevention. Measurement of nucleotide analogs, included in most HIV medication regimens, enables monitoring of short- and long-term adherence and the risk of treatment failure. The REverSe TRanscrIptase Chain Termination (RESTRICT) assay rapidly infers the concentration of intracellular nucleotide analogs based on the inhibition of DNA synthesis by HIV reverse transcriptase enzyme. Here, we introduce a probabilistic model for RESTRICT and demonstrate selective measurement of multiple nucleotide analogs using DNA templates designed according to the chemical structure of each drug. We measure clinically relevant concentrations of tenofovir diphosphate, emtricitabine triphosphate, lamivudine triphosphate, and azidothymidine triphosphate with agreement between experiment and theory. RESTRICT represents a new class of activity-based assays for therapeutic drug monitoring in HIV care and could be extended to other diseases treated with nucleotide analogs.

Citing Articles

Rapid Enzymatic Assay for Antiretroviral Drug Monitoring Using CRISPR-Cas12a-Enabled Readout.

Singh M, Chang M, Wang Q, Rodgers C, Lutz B, Olanrewaju A ACS Synth Biol. 2025; 14(2):510-519.

PMID: 39933068 PMC: 11852202. DOI: 10.1021/acssynbio.4c00674.

REverse transcriptase ACTivity (REACT) assay for point-of-care measurement of established and emerging antiretrovirals for HIV treatment and prevention.

Brainerd C, Singh M, Tatka J, Craig C, Gilligan-Steinberg S, Panpradist N Anal Bioanal Chem. 2024; 416(29):6809-6818.

PMID: 39466376 DOI: 10.1007/s00216-024-05602-4.

Sensitive Pathogen Detection and Drug Resistance Characterization Using Pathogen-Derived Enzyme Activity Amplified by LAMP or CRISPR-Cas.

Wang Q, Kline E, Gilligan-Steinberg S, Lai J, Hull I, Olanrewaju A medRxiv. 2024; .

PMID: 38633802 PMC: 11023665. DOI: 10.1101/2024.03.29.24305085.

REverSe TRanscrIptase chain termination (RESTRICT) for selective measurement of nucleotide analogs used in HIV care and prevention.

Olanrewaju A, Sullivan B, Gim A, Craig C, Sevenler D, Bender A Bioeng Transl Med. 2023; 8(1):e10369.

PMID: 36684094 PMC: 9842053. DOI: 10.1002/btm2.10369.

References

Coulier L, Gerritsen H, van Kampen J, Reedijk M, Luider T, Osterhaus A . Comprehensive analysis of the intracellular metabolism of antiretroviral nucleosides and nucleotides using liquid chromatography-tandem mass spectrometry and method improvement by using ultra performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2011; 879(26):2772-82. DOI: 10.1016/j.jchromb.2011.07.045. View

Kearney B, Flaherty J, Shah J . Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004; 43(9):595-612. DOI: 10.2165/00003088-200443090-00003. View

Castillo-Mancilla J, Zheng J, Rower J, Meditz A, Gardner E, Predhomme J . Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2012; 29(2):384-90. PMC: 3552442. DOI: 10.1089/AID.2012.0089. View

Chen X, Castillo-Mancilla J, Seifert S, McAllister K, Zheng J, Bushman L . Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine. Antimicrob Agents Chemother. 2016; 60(9):5387-92. PMC: 4997838. DOI: 10.1128/AAC.01019-16. View

Chien M, Anderson T, Jockusch S, Tao C, Li X, Kumar S . Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19. J Proteome Res. 2020; 19(11):4690-4697. PMC: 7640960. DOI: 10.1021/acs.jproteome.0c00392. View

Huber H, McCoy J, Seehra J, Richardson C . Human immunodeficiency virus 1 reverse transcriptase. Template binding, processivity, strand displacement synthesis, and template switching. J Biol Chem. 1989; 264(8):4669-78. View

Lofgren S, Nicol M, Kandole T, Castillo-Mancilla J, Anderson P, Mpoza E . Short Communication: A Descriptive Analysis of Dried Blood Spot Adherence Testing Among Ugandans with HIV Presenting with Cryptococcal Meningitis. AIDS Res Hum Retroviruses. 2021; 37(7):529-533. PMC: 8260886. DOI: 10.1089/AID.2020.0202. View

Malmsten A, Shao X, Aperia K, Corrigan G, Sandstrom E, Kallander C . HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma. J Med Virol. 2003; 71(3):347-59. DOI: 10.1002/jmv.10492. View

Dimitrov D, Masse B, Donnell D . PrEP Adherence Patterns Strongly Affect Individual HIV Risk and Observed Efficacy in Randomized Clinical Trials. J Acquir Immune Defic Syndr. 2016; 72(4):444-51. PMC: 4925182. DOI: 10.1097/QAI.0000000000000993. View

10.

Jansen R, Rosing H, Schellens J, Beijnen J . Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs. Mass Spectrom Rev. 2010; 30(2):321-43. DOI: 10.1002/mas.20280. View

11.

Spinelli M, Haberer J, Chai P, Castillo-Mancilla J, Anderson P, Gandhi M . Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions. Curr HIV/AIDS Rep. 2020; 17(4):301-314. PMC: 7363551. DOI: 10.1007/s11904-020-00502-5. View

12.

Singer V, Jones L, YUE S, Haugland R . Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation. Anal Biochem. 1997; 249(2):228-38. DOI: 10.1006/abio.1997.2177. View

13.

Duwal S, Dickinson L, Khoo S, von Kleist M . Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes. PLoS Comput Biol. 2018; 14(6):e1006155. PMC: 6001963. DOI: 10.1371/journal.pcbi.1006155. View

14.

Castillo-Mancilla J, Haberer J . Adherence Measurements in HIV: New Advancements in Pharmacologic Methods and Real-Time Monitoring. Curr HIV/AIDS Rep. 2018; 15(1):49-59. PMC: 5876155. DOI: 10.1007/s11904-018-0377-0. View

15.

Natoli M, Rohrman B, De Santiago C, van Zyl G, Richards-Kortum R . Paper-based detection of HIV-1 drug resistance using isothermal amplification and an oligonucleotide ligation assay. Anal Biochem. 2017; 544:64-71. PMC: 5854266. DOI: 10.1016/j.ab.2017.12.008. View

16.

Anderson P, Kakuda T, Lichtenstein K . The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis. 2004; 38(5):743-53. DOI: 10.1086/381678. View

17.

Drain P, Bardon A, Simoni J, Cressey T, Anderson P, Sevenler D . Point-of-care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and Prevention. Curr HIV/AIDS Rep. 2020; 17(5):487-498. PMC: 7492442. DOI: 10.1007/s11904-020-00512-3. View

18.

Morrow M, MaWhinney S, Coyle R, Coleman S, Gardner E, Zheng J . Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV. J Infect Dis. 2019; 220(4):635-642. PMC: 6639595. DOI: 10.1093/infdis/jiz144. View

19.

Anderson P, Liu A, Castillo-Mancilla J, Gardner E, Seifert S, McHugh C . Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Antimicrob Agents Chemother. 2017; 62(1). PMC: 5740314. DOI: 10.1128/AAC.01710-17. View

20.

Durand-Gasselin L, Da Silva D, Benech H, Pruvost A, Grassi J . Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. Antimicrob Agents Chemother. 2007; 51(6):2105-11. PMC: 1891370. DOI: 10.1128/AAC.00831-06. View